Bausch + Lomb, Corporation received approval to extend its Lumify eye drop line with a preservative-free formulation a month after the first generic of the brimonidine tartrate OTC switch was approved as B+L litigates to protect its patents for the product.
The Canadian firm, which announces its latest results on 1 May, received approval from the Food and Drug Administration in...







